We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012.
- Authors
Mamo, A.; Nogueira, M. Cardoso; Batist, G.; Palumbo, M.; Panasci, L.; Ferrario, C.; Chaudhury, P.; Metrakos, P.; Kavan, P.
- Abstract
Background Panitumumab is a fully human monoclonal antibody, directed against the epidermal growth factor receptor, that was shown to be effective in third-line metastatic colorectal cancer. We performed a retrospective analysis of patients with chemo-refractory non-KRAS-mutated metastatic colorectal cancer, who received panitumumab at the Jewish General Hospital in Montreal, Canada, between 2009 and 2012. Methods This chart review included 44 patients (median age: 60 years; performance status: 0-3), of whom 50% had already received three lines of treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival and safety. Tumour progression was determined by radiologic assessments performed once every 3 months per clinical guidelines or by clinical deterioration as determined by the clinician-investigator. Results In our sample, median PFS was 21.86 ± 5.23 weeks (95% confidence interval: 12.9 to 36.9 weeks) and overall survival was 35.14 ± 7.75 weeks (95% confidence interval: 25.6 to 73.4 weeks) with a median of 5 cycles of panitumumab treatment. The most frequently reported toxicities with panitumumab were skin toxicity (16.2% grade 3) and hypomagnesemia (10.8% grade 3). No infusion reactions were reported. Conclusions Despite a small sample size from a single institution, our survival and efficacy data are encouraging and comparable to results obtained from the registration panitumumab trial. Our findings suggest that panitumumab can be effective and tolerable in a real-world setting.
- Subjects
CANCER chemotherapy; COLON cancer; CANCER patients; EPIDERMAL growth factor receptors; JEWISH General Hospital (Montreal, Quebec)
- Publication
Current Oncology, 2013, Vol 20, Issue 2, pE107
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3747/co.20.1271